Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis

Critical Care Medicine

Volumn 26, Issue 6, 1998, Pages 1001-1006

  Nylen, Eric S ^a,b,d   Whang, Kevin T ^c   Snider Jr , Richard H ^a   Steinwald, Paul M ^b   White, Jon C ^a,b,c   Becker, Kenneth L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anti serum; Calcitonin; Cytokine; Hormone; Immunotherapy; Inflammation; Peritonitis; Procalcitonin; Prohormone; Sepsis

Indexed keywords

ANTISERUM; CALCITONIN; PROCALCITONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE SEVERITY; ESCHERICHIA COLI; IMMUNOTHERAPY; INFLAMMATION; MALE; MORTALITY; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; RAT;

ANIMALS; CALCITONIN; CRICETINAE; ESCHERICHIA COLI INFECTIONS; HUMANS; IMMUNE SERA; IMMUNIZATION, PASSIVE; INJECTIONS, INTRAPERITONEAL; MALE; MESOCRICETUS; PROTEIN PRECURSORS; SEPSIS;

EID: 0031776575     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199806000-00015     Document Type: Article

References (26)

1. Lowry SF: Sepsis and its complications: Clinical definitions and therapeutic prospects. Crit Care Med 1994; 22:S1-S2
2. Neugbauer EA, Holaday JW (Eds): Handbook of Mediators in Septic Shock. Boca Raton, FL, CRC Press, 1993
3. Fisher CJ, Dhainaut J-FA, Opal SM: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with the sepsis syndrome. JAMA 1994; 271:1836-1843
4. Abraham E, Wunderink R, Silerman H: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with the sepsis syndrome: A randomized, controlled, double-blind, multicenter clinical trial. JAMA; 1995; 73:934-941
5. Zeni F, Freeman B, Natanson C: Antiinflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997; 25:1095-1100
6. Christman JW, Holden EP, Blackwell TS: Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med 1995; 23: 955-963
7. Nylen ES, O'Neill W, Jordan MH, et al: Serum procalcitonin as an index of inhalational injury in burns. Horm Metab Res 1992; 24:439-442
8. Nylen ES, Snider RH Jr, Thompson KA, et al: Pneumonitis-associated hyperprocalcitoninemia. Amn Med Sci 1996; 312:12-18
9. Nylen ES, Alarifi A, Snider RH Jr, et al: The effect of classical heat stroke on serum procalcitonin. Crit Care Med 1997; 25:1431-1436
10. Dandona P, Nix D, Wilson MF, et al: Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-1608
11. Assicot M, Gendrel D, Carsin H, et al: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341:515-518
12. Lind L, Bucht E, Ljunghall S: Pronounced elevation in circulating calcitonin in critical care patients is related to the severity of illness and survival. Intensive Care Med 1995; 21:63-66
13. Al-Nawas B, Krammer I, Shah PM: Procalcitonin in diagnosis of severe infections. Eur J Med Res 1995/96; 1: 331-333
14. Zaloga GP: Hypocalcemia in critically ill patients. Crit Care Med 1992; 20:251-262
15. Steinwald PM, Becker KL, Nylen ES, et ai: Hyperprocalcitoninemia of E. coli sepsis in a hamster model: Association with hypocalcemia and hyperphosphatemia. Abstr. 1996, 10th International Congress of Endocrinology, Vol 1, p 359
16. Chesney RW, McCarron DM, Haddad JG, et al: Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome. J Lab Clin Med 1983; 101:576-585
17. Becker KL, Bivins LE, Radfar RH, et al: Study of calcitonin heterogeneity using a radioreceptor assay. Horm Metab Res 1978; 10:457-458
18. Zaidi M, Moonga BS, Bevis PJR, et al: Expression and function of the calcitonin gene products. Vitam Horm 1991; 46:87-164
19. Dunne JR, Dunkin BJ, Nelson S, et al: Effect of granulocyte colony stimulating factor in a non-neutropenic rodent model of Escherichia coli peritonitis. J Surg Res 1996; 61:348-354
20. Nylen ES, Linnoila RI, Snider RH Jr, et al: Comparative studies of hamster calcitonin from pulmonary endocrine cells in vitro. Peptides 1987; 8:977-982
21. Linnoila RI, Becker KL, Silva OL, et al: Calcitonin as a marker for diethylnitrosamine-induced pulmonary endocrine cell hyperplasia in hamsters. Lab Invest 1984; 51:39-45
22. Nylen ES, Becker KL, Snider RH Jr, et al: . Cholinergic-nicotinic control of growth and secretion of cultured pulmonary neuroendocrine cells. Anat Rec 1993; 236:129-135
23. Weiner DL, Kupermann N, Saladino RA, et al: Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis. Crit Care Med 1996; 24:1514-1517
24. Porat R, Paddock HN, Schwaitzberg SD, et al: Glycosylated recombinant tumor necrosis factor binding protein-1 reduced mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis. Crit Care Med 1995; 23:1080-1089
25. Friedland JS, Porter JC, Daryanani S, et al: Plasma proinflammatory cytokine concentrations, acute and chronic health evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit Care Med 1996; 24: 1775-1781
26. Becker KL, Silva OL, Snider RH Jr, et al: The pathophysiology of calcitonin. In: The Endocrine Lung in Health and Disease. Becker KL, Gazdar AF (Eds). Philadelphia, WB Saunders, 1984, pp 277-299